Enanta Pharmaceuticals competitors

Enanta Pharmaceuticals Competitors include Ab Initio Biotherapeutics, OncoTartis, Eternygen and Forge Therapeutics.
Add company...
Enanta Pharmaceuticals
Enanta Pharmaceuticals
Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs.
Ab Initio Biotherapeutics
Ab Initio Biotherapeutics
Ab Initio is engaged in identifying therapeutic antibodies that activate and inactivate G-protein coupled receptors.
OncoTartis
OncoTartis
OncoTartis is a biotechnology company developing a novel category of anti-cancer drugs directed against tissue-specific targets for a subset of cancers.
Eternygen
Eternygen
Eternygen is focusing on research and development of innovative drugs using a network of renowned scientists and contract research organizations.
Forge Therapeutics
Forge Therapeutics
Forge Therapeutics is a biotech that leverages its novel chemistry platform to develop small molecule inhibitors to target metalloproteins.
Founding Date
Founding Date
1998
Founding Date
2015
Founding Date
2009
Founding Date
2012
Founding Date
2015
Type
Type
Public
Type
Private
Type
Private
Type
Private
Type
Private
Tags
Locations
Locations
Watertown, US HQ
Locations
South San Francisco, US HQ
Locations
Buffalo, US HQ
Locations
Berlin, DE HQ
Edinburgh, GB
Locations
San Diego, US HQ
Employees
Employees
89
Employees
4
Employees
4
Employees
6
Employees
14

Funding

Latest funding round
Latest funding round
N/A
Latest funding round
N/A
Latest funding round
$ 6m (about 1 year ago)
Latest funding round
$ 8.4m (almost 2 years ago)
Latest funding round
$ 15m (over 1 year ago)
Total funding raised
Total funding raised
$ 9.2m
Total funding raised
N/A
Total funding raised
$ 6m
Total funding raised
$ 8.4m
Total funding raised
$ 15m
For sources of this data, please see the company profileDownload Excel

View company profiles

Ab Initio Biotherapeutics
HQ
South San Francisco, US
Employees
4

Ab Initio is engaged in identifying therapeutic antibodies that activate and inactivate G-protein coupled receptors.

View company
OncoTartis
HQ
Buffalo, US
Employees
4

OncoTartis is a biotechnology company developing a novel category of anti-cancer drugs directed against tissue-specific targets for a subset of cancers.

View company
Eternygen
HQ
Berlin, DE
Employees
6

Eternygen is focusing on research and development of innovative drugs using a network of renowned scientists and contract research organizations.

View company
Forge Therapeutics
HQ
San Diego, US
Employees
14

Forge Therapeutics is a biotech that leverages its novel chemistry platform to develop small molecule inhibitors to target metalloproteins.

View company